One of the most lethal cancers is pancreatic cancer because of its quick development and deadly prognosis. A probable factor for the limited understanding of the disease progression and the development of successful therapy modalities for pancreatic cancer is the absence of representative models in vitro. Organoid models of pancreatic cancer are 3D structures founded on tumor tissues of patients, cell lines, or genetically modified cells. This model maintains key molecular and histological characteristics of the original disease. Such models overcome limitations of conventional 2D in vitro cultures and animal models, offering a reproducible and scalable tool for studying pancreatic ductal adenocarcinoma (PDAC) and other subtypes.
To closely represent the in vivo tumor microenvironment, advanced in vitro models that co-culture pancreatic cancer organoids with key components of the tumor microenvironment (TME), including cancer-associated fibroblasts, immune cells, and endothelial cells. Stromal interactions, immune evasion, and therapy resistance mechanisms driven by the TME can be studied in these models to better understand tumor biology and potential therapeutic targets.
Organoids from pancreatic cancers are important for drug screening, personalized drug, validation of biomarkers, and studying interactions of tumor and stroma, because of their ability to retain specific alterations and gene expression patterns, as well as their capability for long-term expansion. These traits enable large-scale preclinical studies that have greater relevance than traditional 2D models.
Understanding Disease Progression
With the use of organoids, it is possible to carry out studies on the evolution, invasion, and metastasis of tumors, which aids in deciphering the molecular and cellular drivers of the aggressiveness of pancreatic cancer.
Evaluating Therapeutic Responses
High-throughput drug screening on organoids can predict individual sensitivity or resistance to various therapy methods such as chemotherapy, targeted therapeutics, and immunotherapy, supporting customized therapy strategies.
Identifying Biomarkers
Organoid models facilitate the discovery and validation of predictive and prognostic biomarkers through multi-omic profiling, encompassing genomic, transcriptomic, and proteomic profiling in a controlled experimental setting.
Leveraging deep knowledge in pancreatic cancer biology along with advancements in organoid technologies, Alfa Cytology delivers models that are relevant to the physiology and accelerate the therapeutic discovery and development of biomarkers. Our services span a range of uses, from academic research to pharmaceutical research and development, with an emphasis on precision, scalability, and translational impact.
Alfa Cytology develops a broad spectrum of organoid models of pancreatic cancer, including those derived from PDAC and rare subtype tumor tissues, established cell lines, and genetically engineered cells. Models can be further engineered to introduce specific mutations, reporter genes, or therapeutic targets, providing flexibility for various experimental needs.
In terms of the organoid development process, we are covering all of it, including ethical sample acquisition, tumor dissociation, organoid culture, quality control, and validation of genomics and histopathology. In addition to those, we can incorporate functional assays for drug sensitivity, invasion, and co-culture with immune or stromal cells to enhance overall model applicability.
Beyond model development, we offer a suite of organoid-based research services utilizing validated pancreatic cancer organoid models. These include organoid model-based basic research services such as genetic manipulation, signaling pathway analysis, and mechanistic studies, as well as organoid model-based preclinical research services like high-content drug screening and combination therapy testing, all designed to bridge the gap between in vitro models and application translation.
Alfa Cytology developed a pancreatic ductal adenocarcinoma (PDAC) organoid model and established a physiologically relevant co-culture system by integrating it with matched cancer-associated fibroblasts (CAFs). Organoids were successfully generated from tumor tissues using an optimized digestion and 3D culture protocol. Whole-genome sequencing analysis of these organoids verified the presence of genomic alterations characteristic of PDAC, confirming their disease-specific molecular fidelity. For co-culture, dissociated organoid units and CAFs were combined at a defined ratio within a composite extracellular matrix. This system supported direct cell-cell interactions and, importantly, led to a statistically significant increase in organoid proliferation compared with standard monoculture, thereby providing a robust platform for modeling tumor-stroma interactions and evaluating therapeutic responses.
Fig.1 Development and characterization of PDAC organoid-fibroblast co-culture model. (A) Schematic of the PDAC organoid generation workflow. (B) Proliferation levels of PDAC organoids in monoculture and CAF co-culture. Data are presented as mean ± SEM (n=5; *p < 0.05).
With a focus on scientific excellence and working alongside our clients, Alfa Cytology offers a unique service for developing tailored organoids for pancreatic cancer. Our integrated platform for pancreatic cancer organoid development and downstream analysis provides a reliable, relevant system to advance cancer research and therapeutic discovery. If you would like a tailored project to work on, or if you would like to partner with us to explore the technical details and functionality of our services, please reach out to us.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.
